Lizbeth Blancas-Galicia1,2, Eros Santos-Chávez3, Caroline Deswarte4,5, Quentin Mignac4,5, Isabel Medina-Vera6, Ximena León-Lara3, Manon Roynard4,5, Selma C Scheffler-Mendoza7, Ricardo Rioja-Valencia3, Alexandra Alvirde-Ayala3, Saul O Lugo Reyes3, Tamara Staines-Boone8, Jorge García-Campos8, Omar J Saucedo-Ramírez9, Blanca E Del-Río Navarro9, Antonio Zamora-Chávez10, Arturo López-Larios11, Susana García-Pavón-Osorio12, Eugenia Melgoza-Arcos13, María R Canseco-Raymundo14, Dolores Mogica-Martínez14, Marco Venancio-Hernández14, Daniel Pacheco-Rosas15, Sigifredo Pedraza-Sánchez16, Martha Guevara-Cruz17, Federico Saracho-Weber18, Berenise Gámez-González19, Guillermo Wakida-Kuzunoki20, Ana R Morán-Mendoza21, Ana P Macías-Robles21, Roselia Ramírez-Rivera22, Eugenia Vargas-Camaño23, Carmen Zarate-Hernández24, Héctor Gómez-Tello25, Emmanuel Ramírez-Sánchez26, Fredy Ruíz-Hernández27, Domingo Ramos-López28, Héctor Acuña-Martínez29, María L García-Cruz30, María G Román-Jiménez31, Marina G González-Villarreal32, Aristóteles Álvarez-Cardona33, Beatriz A Llamas-Guillén34, Jennifer Cuellar-Rodríguez35, Alberto Olaya-Vargas36, Nideshda Ramírez-Uribe36, Stéphanie Boisson-Dupuis4,5,37, Jean-Laurent Casanova4,5,37,38,39, Francisco J Espinosa-Rosales40, Jeanet Serafín-López41, Marco Yamazaki-Nakashimada7, Sara Espinosa-Padilla3, Jacinta Bustamante42,43,44,45. 1. Unidad de Investigación en Inmunodeficiencias, Instituto Nacional de Pediatría, Mexico City, Mexico. blancas.lizbeth@gmail.com. 2. Laboratorio de Inmunología molecular II, Escuela Nacional de Ciencias Biológicas, IPN, Mexico City, Mexico. blancas.lizbeth@gmail.com. 3. Unidad de Investigación en Inmunodeficiencias, Instituto Nacional de Pediatría, Mexico City, Mexico. 4. Imagine Institute, Paris University, Paris, France. 5. Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Paris, France. 6. Departamento de Metodología de la Investigación, Instituto Nacional de Pediatría, Mexico City, Mexico. 7. Departamento de Inmunología Clínica, Instituto Nacional de Pediatría, Mexico City, Mexico. 8. Departamento de Inmunología, UMAE # 25, Monterrey, Mexico. 9. Departamento de Alergia, Hospital infantil de México Federico Gómez, Mexico City, Mexico. 10. Departamento de Medicina Interna, Hospital Infantil de México Federico Gómez, Mexico City, Mexico. 11. Unidad de Inmunología Clínica, Hospital CIMA, Hermosillo, Sonora, Mexico. 12. Departamento de Alergia e Inmunología, Hospital Naval, Mexico City, Mexico. 13. Unidad de Terapia Intensiva Pediátrica, Hospital Naval, Mexico City, Mexico. 14. Departamento de Alergia e Inmunología Clínica, UMAE, "LA RAZA", Mexico City, Mexico. 15. Departamento de Infectología Pediátrica, UMAE "Siglo XXI", Mexico City, Mexico. 16. Unidad de Bioquímica, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico. 17. Departamento de Fisiología de la Nutrición, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico. 18. Departamento de Enseñanza, Hospital Infantil de Especialidades, Chihuahua, Mexico. 19. Departamento de Alergia e Inmunología, Hospital Infantil de Especialidades Chihuahua, Chihuahua, Mexico. 20. Departamento de Pediatría, Hospital Central Sur "PEMEX", Mexico City, Mexico. 21. Departamento de Alergia e Inmunología Clínica Pediátrica, UMAE, CMNO, Guadalajara, Mexico. 22. Departamento de Pediatría, Hospital de Especialidades del Niño y la Mujer, "Dr Felipe Nuñez Lara", Querétaro, Mexico. 23. Departamento de Alergia e Inmunología, CMN "20 de Noviembre", Mexico City, Mexico. 24. CRAIC, Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey, Mexico. 25. Departamento de Alergia e Inmunología, Hospital del Niño Poblano, Puebla, Puebla, Mexico. 26. Hospital General de Playa del Carmen, Playa del Carmen, Quintana Roo, Mexico. 27. Departamento de Inmunología, Hospital de la Niñez Oaxaqueña, Oaxaca, Mexico. 28. Departamento de Alergia, Clínica #2, IMSS, San Luis Potosí, Mexico. 29. Departamento de Inmunología, Hospital de Especialidades Pediátricas, Tuxtla Gutiérrez, Chiapas, Mexico. 30. Departamento de Otorrinolaringología, INER, Mexico City, Mexico. 31. Departamento de Traumatología y Ortopedia, UMAE, Hospital de Traumatología y Ortopedia, Puebla, Mexico. 32. Departamento de Hematología Pediátrica, UMAE # 25, Monterrey, Mexico. 33. Departamento de Alergia e Inmunología, Hospital Star Médica, Aguascalientes, Mexico. 34. Departamento de Alergia e Inmunología, Hospital del Niño Morelense, Emiliano Zapata, Morelos, Mexico. 35. Departamento de Infectología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico. 36. Programa de Trasplante de Medula Ósea y Terapia Celular, Instituto Nacional de Pediatría, Mexico City, Mexico. 37. St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA. 38. Howard Hughes Medical Institute, New York, NY, USA. 39. Pediatric Hematology-Immunology Unit, Necker Hospital for Sick Children AP-HP, Paris, France. 40. Fundación Mexicana para Niñas y Niños con Inmunodeficiencias Primarias, A.C, Mexico City, Mexico. 41. Laboratorio de Inmunología molecular II, Escuela Nacional de Ciencias Biológicas, IPN, Mexico City, Mexico. 42. Imagine Institute, Paris University, Paris, France. jacinta.bustamante@inserm.fr. 43. Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Paris, France. jacinta.bustamante@inserm.fr. 44. St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA. jacinta.bustamante@inserm.fr. 45. Study Center for Immunodeficiencies, Necker Hospital for Sick Children, AP-HP, Paris, France. jacinta.bustamante@inserm.fr.
Abstract
PURPOSE: Chronic granulomatous disease (CGD) is a primary immunodeficiency characterized by an inability of phagocytes to produce reactive oxygen species, impairing their killing of various bacteria and fungi. We summarize here the 93 cases of CGD diagnosed in Mexico from 2011 to 2019. METHODS: Thirteen Mexican hospitals participated in this study. We describe the genetic, immunological, and clinical features of the 93 CGD patients from 78 unrelated kindreds. RESULTS: Eighty-two of the patients (88%) were male. All patients developed bacterial infections and 30% suffered from some kind of fungal infection. Fifty-four BCG-vaccinated patients (58%) presented infectious complications of BCG vaccine. Tuberculosis occurred in 29%. Granulomas were found in 56% of the patients. Autoimmune and inflammatory diseases were present in 15% of patients. A biological diagnosis of CGD was made in 89/93 patients, on the basis of NBT assay (n = 6), DHR (n = 27), and NBT plus DHR (n = 56). The deficiency was complete in all patients. The median age of biological diagnosis was 17 months (range, 0-186 months). A genetic diagnosis was made in 83/93 patients (when material was available), corresponding to CYBB (n = 64), NCF1 (n = 7), NCF2 (n = 7), and CYBA (n = 5) mutations. CONCLUSIONS: The clinical manifestations in these Mexican CGD patients were similar to those in patients elsewhere. This cohort is the largest in Latin America. Mycobacterial infections are an important cause of morbidity in Mexico, as in other countries in which tuberculosis is endemic and infants are vaccinated with BCG. X-linked CGD accounted for most of the cases in Mexico, as in other Latin American countries. However, a significant number of CYBA and NCF2 mutations were identified, expanding the spectrum of known causal mutations.
PURPOSE: Chronic granulomatous disease (CGD) is a primary immunodeficiency characterized by an inability of phagocytes to produce reactive oxygen species, impairing their killing of various bacteria and fungi. We summarize here the 93 cases of CGD diagnosed in Mexico from 2011 to 2019. METHODS: Thirteen Mexican hospitals participated in this study. We describe the genetic, immunological, and clinical features of the 93 CGD patients from 78 unrelated kindreds. RESULTS: Eighty-two of the patients (88%) were male. All patients developed bacterial infections and 30% suffered from some kind of fungal infection. Fifty-four BCG-vaccinated patients (58%) presented infectious complications of BCG vaccine. Tuberculosis occurred in 29%. Granulomas were found in 56% of the patients. Autoimmune and inflammatory diseases were present in 15% of patients. A biological diagnosis of CGD was made in 89/93 patients, on the basis of NBT assay (n = 6), DHR (n = 27), and NBT plus DHR (n = 56). The deficiency was complete in all patients. The median age of biological diagnosis was 17 months (range, 0-186 months). A genetic diagnosis was made in 83/93 patients (when material was available), corresponding to CYBB (n = 64), NCF1 (n = 7), NCF2 (n = 7), and CYBA (n = 5) mutations. CONCLUSIONS: The clinical manifestations in these Mexican CGD patients were similar to those in patients elsewhere. This cohort is the largest in Latin America. Mycobacterial infections are an important cause of morbidity in Mexico, as in other countries in which tuberculosis is endemic and infants are vaccinated with BCG. X-linked CGD accounted for most of the cases in Mexico, as in other Latin American countries. However, a significant number of CYBA and NCF2 mutations were identified, expanding the spectrum of known causal mutations.
Authors: Stephen M Graham; Tahmeed Ahmed; Farhana Amanullah; Renee Browning; Vicky Cardenas; Martina Casenghi; Luis E Cuevas; Marianne Gale; Robert P Gie; Malgosia Grzemska; Ed Handelsman; Mark Hatherill; Anneke C Hesseling; Patrick Jean-Philippe; Beate Kampmann; Sushil Kumar Kabra; Christian Lienhardt; Jennifer Lighter-Fisher; Shabir Madhi; Mamodikoe Makhene; Ben J Marais; David F McNeeley; Heather Menzies; Charles Mitchell; Surbhi Modi; Lynne Mofenson; Philippa Musoke; Sharon Nachman; Clydette Powell; Mona Rigaud; Vanessa Rouzier; Jeffrey R Starke; Soumya Swaminathan; Claire Wingfield Journal: J Infect Dis Date: 2012-03-22 Impact factor: 5.226
Authors: A Condino-Neto; R U Sorensen; A C Gómez Raccio; A King; F J Espinosa-Rosales; J L Franco Journal: Allergol Immunopathol (Madr) Date: 2014-10-05 Impact factor: 1.667
Authors: L Berrón-Ruiz; A Morín-Contreras; V Cano-García; M A Yamazaki-Nakashimada; H Gómez-Tello; M E Vargas-Camaño; R Canseco-Raymundo; F Saracho-Weber; D Pietropaolo-Cienfuegos; B Del Río-Navarro; T Staines-Boone; F Espinosa-Rosales; A González-Del Ángel; M M Saenz-de-Ocaris; D Pacheco-Rosas; S Espinosa-Padilla; L Santos-Argumedo; L Blancas-Galicia Journal: Allergol Immunopathol (Madr) Date: 2014-06-02 Impact factor: 1.667
Authors: J Merlijn van den Berg; Elsbeth van Koppen; Anders Ahlin; Bernd H Belohradsky; Ewa Bernatowska; Lucien Corbeel; Teresa Español; Alain Fischer; Magdalena Kurenko-Deptuch; Richard Mouy; Theoni Petropoulou; Joachim Roesler; Reinhard Seger; Marie-José Stasia; Niels H Valerius; Ron S Weening; Baruch Wolach; Dirk Roos; Taco W Kuijpers Journal: PLoS One Date: 2009-04-21 Impact factor: 3.240
Authors: Faris Ghalib Bakri; Michelle Mollin; Sylvain Beaumel; Bénédicte Vigne; Nathalie Roux-Buisson; Adel Mohammed Al-Wahadneh; Raed Mohammed Alzyoud; Wail Ahmad Hayajneh; Ammar Khaled Daoud; Mohammed Elian Abu Shukair; Mansour Fuad Karadshe; Mahmoud Mohammad Sarhan; Jamal Ahmad Wadi Al-Ramahi; Julien Fauré; John Rendu; Marie Jose Stasia Journal: Front Immunol Date: 2021-03-05 Impact factor: 7.561